|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jou A and Hess J: Epidemiology and
molecular biology of head and neck cancer. Oncol Res Treat.
40:328–332. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sawicki M, Szudy A, Szczyrek M, Krawczyk P
and Klatka J: Molecularly targeted therapies in head and neck
cancers. Otolaryngol Pol. 66:307–312. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Filipowicz W, Bhattacharyya SN and
Sonenberg N: Mechanisms of post-transcriptional regulation by
microRNAs: Are the answers in sight? Nat Rev Genet. 9:102–114.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Adams BD, Kasinski AL and Slack FJ:
Aberrant regulation and function of microRNAs in cancer. Curr Biol.
24:R762–R776. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mah SM, Buske C, Humphries RK and
Kuchenbauer F: miRNA*: A passenger stranded in RNA-induced
silencing complex? Crit Rev Eukaryot Gene Expr. 20:141–148. 2010.
View Article : Google Scholar
|
|
8
|
Koshizuka K, Nohata N, Hanazawa T, Kikkawa
N, Arai T, Okato A, Fukumoto I, Katada K, Okamoto Y and Seki N:
Deep sequencing-based microRNA expression signatures in head and
neck squamous cell carcinoma: Dual strands of pre-miR-150 as
antitumor miRNAs. Oncotarget. 8:30288–30304. 2017.PubMed/NCBI
|
|
9
|
Okato A, Arai T, Kojima S, Koshizuka K,
Osako Y, Idichi T, Kurozumi A, Goto Y, Kato M, Naya Y, et al: Dual
strands of pre-miR-150 (miR-150-5p and miR-150-3p) act as antitumor
miRNAs targeting SPOCK1 in naïve and castration-resistant prostate
cancer. Int J Oncol. 51:245–256. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mataki H, Seki N, Mizuno K, Nohata N,
Kamikawaji K, Kumamoto T, Koshizuka K, Goto Y and Inoue H:
Dual-strand tumor-suppressor microRNA-145 (miR-145-5p and
miR-145-3p) coordinately targeted MTDH in lung squamous cell
carcinoma. Oncotarget. 7:72084–72098. 2016.PubMed/NCBI
|
|
11
|
Matsushita R, Yoshino H, Enokida H, Goto
Y, Miyamoto K, Yonemori M, Inoguchi S, Nakagawa M and Seki N:
Regulation of UHRF1 by dual-strand tumor-suppressor microRNA-145
(miR-145-5p and miR-145-3p): Inhibition of bladder cancer cell
aggressiveness. Oncotarget. 7:28460–28487. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Matsushita R, Seki N, Chiyomaru T,
Inoguchi S, Ishihara T, Goto Y, Nishikawa R, Mataki H, Tatarano S,
Itesako T, et al: Tumour-suppressive microRNA-144-5p directly
targets CCNE1/2 as potential prognostic markers in bladder cancer.
Br J Cancer. 113:282–289. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yonemori M, Seki N, Yoshino H, Matsushita
R, Miyamoto ZK, Nakagawa M and Enokida H: Dual tumor-suppressors
miR-139-5p and miR-139-3p targeting matrix metalloprotease 11 in
bladder cancer. Cancer Sci. 107:1233–1242. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Karatas OF, Yuceturk B, Suer I, Yilmaz M,
Cansiz H, Solak M, Ittmann M and Ozen M: Role of miR-145 in human
laryngeal squamous cell carcinoma. Head Neck. 38:260–266. 2016.
View Article : Google Scholar
|
|
15
|
Huang SH and O'Sullivan B: Overview of the
8th edition TNM classification for head and neck cancer. Curr Treat
Options Oncol. 18:402017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fukumoto I, Hanazawa T, Kinoshita T,
Kikkawa N, Koshizuka K, Goto Y, Nishikawa R, Chiyomaru T, Enokida
H, Nakagawa M, et al: MicroRNA expression signature of oral
squamous cell carcinoma: Functional role of microRNA-26a/b in the
modulation of novel cancer pathways. Br J Cancer. 112:891–900.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Koshizuka K, Hanazawa T, Fukumoto I,
Kikkawa N, Matsushita R, Mataki H, Mizuno K, Okamoto Y and Seki N:
Dual-receptor (EGFR and c-MET) inhibition by tumor- suppressive
miR-1 and miR-206 in head and neck squamous cell carcinoma. J Hum
Genet. 62:113–121. 2017. View Article : Google Scholar
|
|
18
|
Nohata N, Sone Y, Hanazawa T, Fuse M,
Kikkawa N, Yoshino H, Chiyomaru T, Kawakami K, Enokida H, Nakagawa
M, et al: miR-1 as a tumor suppressive microRNA targeting TAGLN2 in
head and neck squamous cell carcinoma. Oncotarget. 2:29–42. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Goto Y, Kojima S, Nishikawa R, Enokida H,
Chiyomaru T, Kinoshita T, Nakagawa M, Naya Y, Ichikawa T and Seki
N: The microRNA-23b/27b/24-1 cluster is a disease progression
marker and tumor suppressor in prostate cancer. Oncotarget.
5:7748–7759. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Arai T, Okato A, Kojima S, Idichi T,
Koshizuka K, Kurozumi A, Kato M, Yamazaki K, Ishida Y, Naya Y, et
al: Regulation of spindle and kinetochore-associated protein 1 by
antitumor miR-10a-5p in renal cell carcinoma. Cancer Sci.
108:2088–2101. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kurozumi A, Goto Y, Matsushita R, Fukumoto
I, Kato M, Nishikawa R, Sakamoto S, Enokida H, Nakagawa M, Ichikawa
T, et al: Tumor-suppressive microRNA-223 inhibits cancer cell
migration and invasion by targeting ITGA3/ITGB1 signaling in
prostate cancer. Cancer Sci. 107:84–94. 2016. View Article : Google Scholar
|
|
22
|
Esquela-Kerscher A and Slack FJ: Oncomirs
- microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nohata N, Hanazawa T, Kikkawa N, Sakurai
D, Fujimura L, Chiyomaru T, Kawakami K, Yoshino H, Enokida H,
Nakagawa M, et al: Tumour suppressive microRNA-874 regulates novel
cancer networks in maxillary sinus squamous cell carcinoma. Br J
Cancer. 105:833–841. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fukumoto I, Kinoshita T, Hanazawa T,
Kikkawa N, Chiyomaru T, Enokida H, Yamamoto N, Goto Y, Nishikawa R,
Nakagawa M, et al: Identification of tumour suppressive
microRNA-451a in hypopharyngeal squamous cell carcinoma based on
microRNA expression signature. Br J Cancer. 111:386–394. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Goto Y, Kojima S, Nishikawa R, Kurozumi A,
Kato M, Enokida H, Matsushita R, Yamazaki K, Ishida Y, Nakagawa M,
et al: MicroRNA expression signature of castration-resistant
prostate cancer: The microRNA-221/222 cluster functions as a tumour
suppressor and disease progression marker. Br J Cancer.
113:1055–1065. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Goto Y, Kurozumi A, Nohata N, Kojima S,
Matsushita R, Yoshino H, Yamazaki K, Ishida Y, Ichikawa T, Naya Y,
et al: The microRNA signature of patients with sunitinib failure:
Regulation of UHRF1 pathways by microRNA-101 in renal cell
carcinoma. Oncotarget. 7:59070–59086. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Osako Y, Seki N, Koshizuka K, Okato A,
Idichi T, Arai T, Omoto I, Sasaki K, Uchikado Y, Kita Y, et al:
Regulation of SPOCK1 by dual strands of pre-miR-150 inhibit cancer
cell migration and invasion in esophageal squamous cell carcinoma.
J Hum Genet. Jun 29–2017.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xia W, Chen Q, Wang J, Mao Q, Dong G, Shi
R, Zheng Y, Xu L and Jiang F: DNA methylation mediated silencing of
microRNA-145 is a potential prognostic marker in patients with lung
adenocarcinoma. Sci Rep. 5:169012015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yang P, Yang Y, An W, Xu J, Zhang G, Jie J
and Zhang Q: The long noncoding RNA-ROR promotes the resistance of
radiotherapy for human colorectal cancer cells by targeting the
p53/miR-145 pathway. J Gastroenterol Hepatol. 32:837–845. 2017.
View Article : Google Scholar
|
|
30
|
Wood NB, Kotelnikov V, Caldarelli DD,
Hutchinson J, Panje WR, Hegde P, Leurgans S, LaFollette S, Taylor
SG IV, Preisler HD, et al: Mutation of p53 in squamous cell cancer
of the head and neck: Relationship to tumor cell proliferation.
Laryngoscope. 107:827–833. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Goto Y, Kurozumi A, Arai T, Nohata N,
Kojima S, Okato A, Kato M, Yamazaki K, Ishida Y, Naya Y, et al:
Impact of novel miR-145-3p regulatory networks on survival in
patients with castration-resistant prostate cancer. Br J Cancer.
117:409–420. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Pashaei E, Guzel E, Ozgurses ME, Demirel
G, Aydin N and Ozen M: A Meta-analysis: Identification of common
mir-145 target genes that have similar behavior in different GEO
datasets. PLoS One. 11:e01614912016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sachdeva M and Mo YY: miR-145-mediated
suppression of cell growth, invasion and metastasis. Am J Transl
Res. 2:170–180. 2010.PubMed/NCBI
|
|
34
|
Das AV and Pillai RM: Implications of miR
cluster 143/145 as universal anti-oncomiRs and their dysregulation
during tumorigenesis. Cancer Cell Int. 15:922015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ohmura G, Tsujikawa T, Yaguchi T, Kawamura
N, Mikami S, Sugiyama J, Nakamura K, Kobayashi A, Iwata T, Nakano
H, et al: Aberrant myosin 1b expression promotes cell migration and
lymph node metastasis of HNSCC. Mol Cancer Res. 13:721–731. 2015.
View Article : Google Scholar
|
|
36
|
Salas-Cortes L, Ye F, Tenza D, Wilhelm C,
Theos A, Louvard D, Raposo G and Coudrier E: Myosin Ib modulates
the morphology and the protein transport within multi-vesicular
sorting endosomes. J Cell Sci. 118:4823–4832. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Fuse M, Nohata N, Kojima S, Sakamoto S,
Chiyomaru T, Kawakami K, Enokida H, Nakagawa M, Naya Y, Ichikawa T,
et al: Restoration of miR-145 expression suppresses cell
proliferation, migration and invasion in prostate cancer by
targeting FSCN1. Int J Oncol. 38:1093–1101. 2011.PubMed/NCBI
|
|
38
|
Nishikawa R, Goto Y, Sakamoto S, Chiyomaru
T, Enokida H, Kojima S, Kinoshita T, Yamamoto N, Nakagawa M, Naya
Y, et al: Tumor-suppressive microRNA-218 inhibits cancer cell
migration and invasion via targeting of LASP1 in prostate cancer.
Cancer Sci. 105:802–811. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kinoshita T, Nohata N, Watanabe-Takano H,
Yoshino H, Hidaka H, Fujimura L, Fuse M, Yamasaki T, Enokida H,
Nakagawa M, et al: Actin-related protein 2/3 complex subunit 5
(ARPC5) contributes to cell migration and invasion and is directly
regulated by tumor-suppressive microRNA-133a in head and neck
squamous cell carcinoma. Int J Oncol. 40:1770–1778. 2012.PubMed/NCBI
|
|
40
|
Idichi T, Seki N, Kurahara H, Yonemori K,
Osako Y, Arai T, Okato A, Kita Y, Arigami T, Mataki Y, et al:
Regulation of actin-binding protein ANLN by antitumor miR-217
inhibits cancer cell aggressiveness in pancreatic ductal
adenocarcinoma. Oncotarget. 8:53180–53193. 2017.PubMed/NCBI
|
|
41
|
Yamada A, Mamane A, Lee-Tin-Wah J, Di
Cicco A, Prévost C, Lévy D, Joanny JF, Coudrier E and Bassereau P:
Catch-bond behaviour facilitates membrane tubulation by
non-processive myosin 1b. Nat Commun. 5:36242014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Komaba S and Coluccio LM: Localization of
myosin 1b to actin protrusions requires phosphoinositide binding. J
Biol Chem. 285:27686–27693. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Almeida CG, Yamada A, Tenza D, Louvard D,
Raposo G and Coudrier E: Myosin 1b promotes the formation of
post-Golgi carriers by regulating actin assembly and membrane
remodelling at the trans-Golgi network. Nat Cell Biol. 13:779–789.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Makowska KA, Hughes RE, White KJ, Wells CM
and Peckham M: Specific myosins control actin organization, cell
morphology, and migration in prostate cancer cells. Cell Rep.
13:2118–2125. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Qi H, Liu S, Guo C, Wang J, Greenaway FT
and Sun MZ: Role of annexin A6 in cancer. Oncol Lett. 10:1947–1952.
2015.PubMed/NCBI
|
|
46
|
Shimizu T, Kasamatsu A, Yamamoto A, Koike
K, Ishige S, Takatori H, Sakamoto Y, Ogawara K, Shiiba M, Tanzawa
H, et al: Annexin A10 in human oral cancer: Biomarker for tumoral
growth via G1/S transition by targeting MAPk signaling pathways.
PLoS One. 7:e455102012. View Article : Google Scholar : PubMed/NCBI
|
